Table of Content

Chapter 1. Executive Summary: Global Chronic Obstructive Pulmonary Disease Market
Chapter 2. Research Methodology & Research Framework

2.1. Research Objective
2.2. Product Overview
2.3. Market Segmentation
2.4. Qualitative Research
2.4.1. Primary & Secondary Sources
2.5. Quantitative Research
2.5.1. Primary & Secondary Sources
2.6. Breakdown of Primary Research Respondents, By Region
2.7. Assumption for Study
2.8. Market Size Estimation
2.9. Data Triangulation

Chapter 3. Global Chronic Obstructive Pulmonary Disease Market Overview

3.1. Industry Value Chain Analysis
3.1.1. Material Provider
3.1.2. Manufacturer
3.1.3. Distributor
3.1.4. End Users
3.2. Industry Outlook
3.2.1. Overview of Chronic Obstructive Pulmonary Disease Market
3.2.2. EXIM Data
3.3. PESTLE Analysis
3.4. Porter's Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitutes
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Dynamics and Trends
3.5.1. Growth Drivers
3.5.1.1. Increasing Prevalence of COPD
3.5.2. Restraints
3.5.2.1. High Cost of Treatment
3.5.3. Opportunity
3.5.3.1 Development of Innovative Therapies and Treatment
3.5.4. Key Trend
3.6. Market Growth and Outlook
3.6.1. Market Revenue Estimates and Forecast (US$ Mn), 2025 – 2035
3.6.2. Price Trend Analysis

Chapter 4. Competition Dashboard

4.1. Market Concentration Rate
4.2. Company Market Share Analysis (Value %), 2025
4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Chronic Obstructive Pulmonary Disease Market Analysis

5.1. Key Insights
5.2. Market Size and Forecast, 2026-2035 (US$ Mn)
5.2.1. By Type
5.2.1.1. Chronic Bronchitis
5.2.1.2. Emphysema
5.2.2. By Treatment Type
5.2.2.1. Drugs
5.2.2.2. Bronchodilator Monotherapy
5.2.2.3. Short-Acting Beta2-Agonists (SABAS)
5.2.2.4. Long-Acting Beta2-Agonists (LABAS)
5.2.2.5. Anti-Cholinergic Agents
5.2.2.6. Anti-Inflammatory Drugs
5.2.2.7. Oral And Inhaled Corticosteroids
5.2.2.8. Anti-Leukotrienes
5.2.2.9. Surgery
5.2.2.10. Lung Volume Reduction Surgery (LVRS)
5.2.2.11. Lung Transplant, Bullectomy
5.2.2.12. Others
5.2.2.13. Oxygen Therapy
5.2.3. By End User
5.2.3.1. Hospitals
5.2.3.2. Homecare Settings
5.2.3.3. Clinics
5.2.3.4. Others
5.2.4. By Region
5.2.4.1. North America
5.2.4.1.1. The U.S.
5.2.4.1.2. Canada
5.2.4.1.3. Mexico
5.2.4.2. Europe
5.2.4.2.1. Western Europe
5.2.4.2.1.1. The UK
5.2.4.2.1.2. Germany
5.2.4.2.1.3. France
5.2.4.2.1.4. Italy
5.2.4.2.1.5. Spain
5.2.4.2.1.6. Rest of Western Europe
5.2.4.2.2. Eastern Europe
5.2.4.2.2.1. Poland
5.2.4.2.2.2. Russia
5.2.4.2.2.3. Rest of Eastern Europe
5.2.4.3. Asia Pacific
5.2.4.3.1. China
5.2.4.3.2. India
5.2.4.3.3. Japan
5.2.4.3.4. South Korea
5.2.4.3.5. Australia & New Zealand
5.2.4.3.6. ASEAN
5.2.4.3.7. Rest of Asia Pacific
5.2.4.4. Middle East & Africa
5.2.4.4.1. UAE
5.2.4.4.2. Saudi Arabia
5.2.4.4.3. South Africa
5.2.4.4.4. Rest of MEA
5.2.4.5. South America
5.2.4.5.1. Argentina
5.2.4.5.2. Brazil
5.2.4.5.3. Rest of South America

Chapter 6. North America Chronic Obstructive Pulmonary Disease Market Analysis

6.1. Market Dynamics and Trends
6.1.1. Growth Drivers
6.1.2. Restraints
6.1.3. Opportunity
6.1.4. Key Trends
6.2. Market Size and Forecast, 2026-2035 (US$ Mn)
6.2.1. By Type
6.2.2. By Treatment Type
6.2.3. By End User 
6.2.4. By Region

Chapter 7. Europe Chronic Obstructive Pulmonary Disease Market Analysis

7.1. Market Dynamics and Trends
7.1.1. Growth Drivers
7.1.2. Restraints
7.1.3. Opportunity
7.1.4. Key Trends
7.2. Market Size and Forecast, 2026-2035 (US$ Mn)
7.2.1. By Type
7.2.2. By Treatment Type
7.2.3. By End User 
7.2.4. By Region

Chapter 8. Asia Pacific Chronic Obstructive Pulmonary Disease Market Analysis

8.1. Market Dynamics and Trends
8.1.1. Growth Drivers
8.1.2. Restraints
8.1.3. Opportunity
8.1.4. Key Trends
8.2. Market Size and Forecast, 2026-2035 (US$ Mn)
8.2.1. By Type
8.2.2. By Treatment Type
8.2.3. By End User 
8.2.4. By Region

Chapter 9. Middle East & Africa Chronic Obstructive Pulmonary Disease Market Analysis

9.1. Market Dynamics and Trends
9.1.1. Growth Drivers
9.1.2. Restraints
9.1.3. Opportunity
9.1.4. Key Trends
9.2. Market Size and Forecast, 2026-2035 (US$ Mn)
9.2.1. By Type
9.2.2. By Treatment Type
9.2.3. By End User 
9.2.4. By Region

Chapter 10. South America Chronic Obstructive Pulmonary Disease Market Analysis

10.1. Market Dynamics and Trends
10.1.1. Growth Drivers
10.1.2. Restraints
10.1.3. Opportunity
10.1.4. Key Trends
10.2. Market Size and Forecast, 2026-2035 (US$ Mn)
10.2.1. By Type
10.2.2. By Treatment Type
10.2.3. By End User 
10.2.4. By Region

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

11.1. AstraZeneca
11.2. Boehringer Ingelheim International GmbH
11.3. GlaxoSmithKline plc
11.4. Novartis AG
11.5. CHIESI Farmaceutici SpA
11.6. Sunovion Pharmaceuticals Inc
11.7. Teva Pharmaceutical Industries Ltd.
11.8. Mylan N.V.
11.9. Orion Corporation
11.10. Merck & Co., Inc.
11.11. Grifols, S.A.
11.12. Abbott
11.13. F. Hoffmann-La Roche Ltd.
11.14. Vectura Group plc
11.15. Pfizer Inc.
11.16. Alkermes
11.17. Almirall, S.A
11.18. Genentech, Inc.
11.19. Biogen
11.20. Astellas Pharma Inc.
11.21. Others

Chapter 12. Annexure

12.1. List of Secondary Sources
12.2. Macro Economic Outlook/Indicators